---

---

tags : Ongoing    crawled time : 20:20   

save search

---

Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
MOLN | $3.61 -6.23% -3.54% 210 |

Professional, Scientific, and T...

| Email alert Add to watchlist
mp0533 first positive ongoing aml meeting trial molecular

---

Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
CNTA | News | $9.46 0.64% 0.79% 0 |

Manufacturing

| Email alert Add to watchlist
year treatment ongoing pharmaceuticals study

---

Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
Published: 2023-12-09 (Crawled : 20:20) - globenewswire.com
GLPG | News | $28.77 -2.31% -2.33% 1.5K |

Health Technology

| Email alert Add to watchlist
GLPGF | News | $35.5157 71.75% 4.8K |

Health Technology

| Email alert Add to watchlist
cd19 glpg5201 ongoing glpg5101 car-t

---

Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome
Published: 2023-11-11 (Crawled : 20:20) - prnewswire.com
IONS | $42.45 1.46% 1.45% 730K |

Health Technology

| Email alert Add to watchlist
ion582 positive update ongoing trial

---

FARFETCH ONGOING DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Farfetch To Contact Him Directly To Discuss Their Options
Published: 2023-10-29 (Crawled : 20:20) - prnewswire.com
FTCH | $0.6428 -13.26% -34.66% 0 |

Technology Services

| -53.7% | O: -4.88% H: 3.21% C: -5.13%
ADBE A | $477.12 0.89% 0.96% 1.7M |

Technology Services

| -6.1% | O: 1.57% H: 2.84% C: 2.1%
deadline ongoing

---

Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
Published: 2023-06-03 (Crawled : 20:20) - globenewswire.com
COGT | $6.54 -6.03% -6.34% 5 |

Health Technology

| Email alert Add to watchlist
bezuclastinib tumors positive ongoing gastrointestinal trial

---

Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial
Published: 2023-05-21 (Crawled : 20:20) - globenewswire.com
IMMX | $2.13 -7.39% -6.98% 14 |

| 29.88% | O: 17.68% H: 0.0% C: -9.33%
nxc-201 positive biopharma ongoing trial response results

---

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022
Published: 2022-11-05 (Crawled : 20:20) - globenewswire.com
NTLA | $21.17 -1.67% -1.75% 710K |

Health Technology

| Email alert Add to watchlist
ntla-2001 sessions treatment ongoing arm crispr heart therapy study

---

Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting
Published: 2022-10-22 (Crawled : 20:20) - globenewswire.com
VRDN | $13.03 -8.56% -9.28% 770K |

Health Care and Social Assistan...

| Email alert Add to watchlist
vrdn-001 ongoing thyroid disease active meeting eye trial positive

---

Plus Therapeutics Presents Positive Data from Ongoing ReSPECT™ Clinical Trials at the Annual Conference on CNS Clinical Trials and Brain Metastases
Published: 2022-08-13 (Crawled : 20:20) - globenewswire.com
PSTV | News | $1.6 -1.84% -5.16% 8.5K |

Health Technology

| Email alert Add to watchlist
ongoing trials conference therapeutics plus positive train brain metastases

---

4D Molecular Therapeutics Presents Interim Results from the Ongoing 4D-125 Phase 1/2 Clinical Trial in Patients with Advanced X-linked Retinitis Pigmentosa at the ASRS Annual Meeting
Published: 2021-10-10 (Crawled : 20:20) - globenewswire.com
FDMT M | $24.25 -2.26% -2.29% 290K |

Health Technology

| 0.71% | O: -5.81% H: 16.67% C: 14.68%
ongoing phase 1 results molecular trial

---

Gainers vs Losers

61%

39%

Top 10 Gainers

BOF | $2.08 77.78% 39.06% 110M |

BHIL | $0.1793 -4.37% 19.24% 340K |

Agriculture, Forestry, Fishing ...

UMAC | $1.48 -1.33% 14.87% 20K |

CI | $352.28 -0.11% 13.53% 2 |

Health Services

CIG.C | $2.89 -1.37% 12.8% 2.3K |

n/a

MTH | $154.69 -2.21% 12.68% 450K |

Consumer Durables

HCP | News | $31.41 7.75% 11.26% 1.2M |

BMTX 4 | $1.545 0.98% 10.03% 2.5K |

Information

TAL | $12.26 0.57% 9.22% 12M |

Consumer Services

ASXC | $0.243 -2.41% 7.0% 1.1M |

Manufacturing

---

Your saved searches

---